Clinical Trial Update: Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating cadonilimab plus chemotherapy as first-line treatment for PD-L1 negative non-small cell lung cancer, with patient recruitment ongo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: NSCLC | Phase 2 | Status: RECRUITING